Blood product transfusion practices in neonates with hypoxic-ischemic encephalopathy

Atiyeh A Miran1, Michelle Stoopler2, Mehmet Nevzat Cizmeci1

  • 1Division of Neonatology, Department of Paediatrics, Hospital for Sick Children, Toronto, ON, M5G 1×8, Canada.

Insights

Blood product transfusions in infants with hypoxic-ischemic encephalopathy (HIE) undergoing therapeutic hypothermia (TH) showed no link to death or neurodevelopmental issues. Further research is needed to clarify optimal transfusion strategies for HIE infants.

Area of Science:

  • Neonatalogy
  • Pediatric Critical Care
  • Hematology

Background:

  • Therapeutic hypothermia (TH) is standard for hypoxic-ischemic encephalopathy (HIE).
  • Blood product transfusion is common in HIE infants during TH.
  • Transfusion practices and their impact in this population are not well understood.

Purpose of the Study:

  • To describe blood product transfusion practices in infants with HIE.
  • To examine the association between transfusion practices and infant outcomes.

Main Methods:

  • Retrospective cohort study at a single Level IV NICU.
  • Evaluation of transfusion thresholds.
  • Analysis of hematological abnormalities and blood product transfusions in relation to outcomes.

Main Results:

  • Univariate analysis suggested FFP transfusion was linked to increased in-hospital death.
  • Multivariate analysis, controlling for HIE severity, found no association between transfusion and death.
  • No association was observed between transfusion and neurodevelopmental impairment.

Conclusions:

  • Blood product transfusion in HIE infants during TH was not associated with death or neurodevelopmental impairment in this study.
  • Findings suggest current transfusion practices may be safe, but further investigation is warranted.
  • Optimal transfusion thresholds for HIE infants require further study.
Abstract